Cantor Fitzgerald Maintains Overweight Rating On Amgen With $405 Price Target, Projecting $33.2B Revenue In 2024; Highlights Pipeline Risks And -4% BMD Loss In AMG-133 Phase 1 Trial
Cantor Fitzgerald Maintains Overweight Rating On Amgen With $405 Price Target, Projecting $33.2B Revenue In 2024; Highlights Pipeline Risks And -4% BMD Loss In AMG-133 Phase 1 Trial
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.